sedation. Use Caution/Monitor.papaverinechlorpromazine and papaverine both increase sedation. Use Caution/Monitor.paroxetinechlorpromazine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.pasireotidechlorpromazine and pasireotide both decrease QTc interval. Modify Therapy/Monitor Closely.pazopanibchlorpromazine and pazopanib both increase QTc interval. Use Caution/Monitor.peginterferon alfa 2bpeginterferon alfa 2b, chlorpromazine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.pentazocinepentazocine and chlorpromazine both increase sedation. Use Caution/Monitor.pentobarbitalpentobarbital and chlorpromazine both increase sedation. Use Caution/Monitor.perphenazinechlorpromazine and perphenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and perphenazine both increase sedation. Use Caution/Monitor.phendimetrazinechlorpromazine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, phendimetrazine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.phenobarbitalphenobarbital and chlorpromazine both increase sedation. Use Caution/Monitor.phenterminechlorpromazine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, phentermine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.phenylephrinechlorpromazine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, phenylephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.phenylephrine POchlorpromazine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .chlorpromazine, phenylephrine PO. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.pholcodinechlorpromazine and pholcodine both increase sedation. Use Caution/Monitor.pimozidechlorpromazine and pimozide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and pimozide both increase sedation. Use Caution/Monitor.pirbuterolchlorpromazine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.porfimerchlorpromazine, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.posaconazolechlorpromazine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.pralidoximepralidoxime decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.pralidoxime decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of pralidoxime by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.primidoneprimidone and chlorpromazine both increase sedation. Use Caution/Monitor.procarbazineprocarbazine, chlorpromazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Excessive sedation.prochlorperazinechlorpromazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and prochlorperazine both increase sedation. Use Caution/Monitor.promethazinechlorpromazine and promethazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.promethazine and chlorpromazine both increase sedation. Use Caution/Monitor.propanthelinepropantheline decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.propantheline decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of propantheline by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.propofolpropofol and chlorpromazine both increase sedation. Use Caution/Monitor.propylhexedrinechlorpromazine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, propylhexedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.protriptylinechlorpromazine and protriptyline both increase sedation. Use Caution/Monitor.pseudoephedrinechlorpromazine, pseudoephedrine. Mechanism: unknown. Use Caution/Monitor. Consider avoiding use of pseudoephedrine in patients receiving phenothiazines (especially thioridazine) due to the potential risk of cardiac arrhythmia or sudden death. Monitor for evidence of ventricular arrhythmias during concomitant use.quazepamquazepam and chlorpromazine both increase sedation. Use Caution/Monitor.quetiapinechlorpromazine and quetiapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and quetiapine both increase sedation. Use Caution/Monitor.quetiapine, chlorpromazine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT.quinidinequinidine will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.quininechlorpromazine and quinine both increase QTc interval. Use Caution/Monitor.ramelteonchlorpromazine and ramelteon both increase sedation. Use Caution/Monitor.ranolazinechlorpromazine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.rapacuroniumrapacuronium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.rapacuronium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of rapacuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rilpivirinerilpivirine increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.rimabotulinumtoxinBchlorpromazine, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.risperidonechlorpromazine and risperidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.chlorpromazine and risperidone both increase sedation. Use Caution/Monitor.rocuroniumrocuronium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.rocuronium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of rocuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.rolapitantrolapitant will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.romidepsinchlorpromazine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.salmeterolchlorpromazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.saquinavirsaquinavir, chlorpromazine. Either increases toxicity of the other by QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available. Increased risk of PR or QT prolongation and cardiac arrhythmias.scopolaminescopolamine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.scopolamine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of scopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.scullcapchlorpromazine and scullcap both increase sedation. Use Caution/Monitor.secobarbitalsecobarbital and chlorpromazine both increase sedation. Use Caution/Monitor.selpercatinibselpercatinib increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidatechlorpromazine, serdexmethylphenidate/dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.sevofluranesevoflurane and chlorpromazine both increase sedation. Use Caution/Monitor.shepherd's pursechlorpromazine and shepherd's purse both increase sedation. Use Caution/Monitor.smokingsmoking decreases levels of chlorpromazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.sodium picosulfate/magnesium oxide/anhydrous citric acidsodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of chlorpromazine by cation binding in GI tract. Use Caution/Monitor. Take at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid to avoid magnesium chelation .sodium sulfate/?magnesium sulfate/potassium chloridesodium sulfate/?magnesium sulfate/potassium chloride decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer chlorpromazine at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .sodium sulfate/potassium sulfate/magnesium sulfatesodium sulfate/potassium sulfate/magnesium sulfate decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer chlorpromazine at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias. .solifenacinsolifenacin decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.solifenacin decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.sorafenibsorafenib and chlorpromazine both increase QTc interval. Use Caution/Monitor.stiripentolstiripentol, chlorpromazine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.sufentanilsufentanil and chlorpromazine both increase sedation. Use Caution/Monitor.sulfamethoxazolechlorpromazine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.tamoxifenchlorpromazine, tamoxifen. affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. CYP2D6 inhibition decreases metabolism of tamoxifen to hydroxytamoxifen, and N-desmethyl tamoxifen to endoxifen (active metabolites with 100-fold greater affinity for estrogen receptor); decreased endoxifen levels may result in poor clinical outcome.tamsulosinchlorpromazine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.tapentadoltapentadol and chlorpromazine both increase sedation. Use Caution/Monitor.teduglutideteduglutide increases levels of chlorpromazine by Other (see comment). Use Caution/Monitor. Comment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary.telavancinchlorpromazine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamtemazepam and chlorpromazine both increase sedation. Use Caution/Monitor.terbinafineterbinafine will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.terbutalinechlorpromazine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.tetrabenazinechlorpromazine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.thalidomidethalidomide increases effects of chlorpromazine by unspecified interaction mechanism. Use Caution/Monitor. Increased sedative effects.thioridazinechlorpromazine and thioridazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and thioridazine both increase sedation. Use Caution/Monitor.thiothixenechlorpromazine and thiothixene both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and thiothixene both increase sedation. Use Caution/Monitor.tiotropiumtiotropium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tiotropium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of tiotropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.tobacco usetobacco use decreases levels of chlorpromazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.tolterodinetolterodine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.tolterodine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of tolterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.topiramatechlorpromazine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadoltramadol and chlorpromazine both increase sedation. Use Caution/Monitor.tranylcyprominetranylcypromine, chlorpromazine. Other (see comment). Use Caution/Monitor. Comment: Coadministration of MAOI and phenothiazines may lead to additive hypotensive effects.trazodonechlorpromazine and trazodone both increase sedation. Use Caution/Monitor.triazolamtriazolam and chlorpromazine both increase sedation. Use Caution/Monitor.triclofostriclofos and chlorpromazine both increase sedation. Use Caution/Monitor.trifluoperazinechlorpromazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and trifluoperazine both increase sedation. Use Caution/Monitor.trihexyphenidyltrihexyphenidyl decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimchlorpromazine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipraminechlorpromazine and trimipramine both increase sedation. Use Caution/Monitor.triprolidinetriprolidine and chlorpromazine both increase sedation. Use Caution/Monitor.triptorelintriptorelin increases toxicity of chlorpromazine by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.tropisetronchlorpromazine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chloridetrospium chloride decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.trospium chloride decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of trospium chloride by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.valbenazinechlorpromazine will increase the level or effect of valbenazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Consider reducing valbenazine dose based on tolerability if coadministered with a strong CYP2D6 inhibitor.valbenazine and chlorpromazine both increase QTc interval. Use Caution/Monitor.valoctocogene roxaparvovecchlorpromazine and valoctocogene roxaparvovec both increase Other (see comment). Use Caution/Monitor. Medications that may cause hepatotoxicity when combined with valoctogene roxaparvovec may potentiate the risk of elevated liver enzymes. Closely monitor these medications and consider alternative medications in case of potential drug interactions.vecuroniumvecuronium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.vecuronium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of vecuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.venlafaxinevenlafaxine will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.chlorpromazine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.voclosporinvoclosporin, chlorpromazine. Either increases effects of the